The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
June 2017
in “
Advances in Therapy
”
TLDR New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
The 2017 document reviewed the challenges and emerging treatments for Alopecia Areata (AA), highlighting the lack of FDA-approved treatments for extensive AA at the time and the need for better therapeutic options. It discussed the role of various cytokines in AA's pathogenesis and the potential of JAK inhibitors like ruxolitinib, tofacitinib, and baricitinib, which were in clinical trials and showed promise in inducing hair regrowth. The document also mentioned other treatments such as PDE4 inhibitors, with apremilast showing potential, and IL-23 inhibitors like ustekinumab, which demonstrated significant hair regrowth in patients. It noted the mixed results of other biological agents and the need for large, placebo-controlled clinical trials to establish the safety and efficacy of these treatments. The document concluded that the therapeutic paradigm for AA was likely to change significantly with the introduction of targeted drugs, similar to the advancements seen in psoriasis and atopic dermatitis treatment.
View this study on link.springer.com →
Cited in this study
23 / results
research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report
A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research Biomarkers of Alopecia Areata Disease Activity and Response to Corticosteroid Treatment
Corticosteroid treatment reduces inflammation and alters hair keratins in alopecia areata.
research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism
Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing
Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Alopecia Universalis Successfully Treated With Adalimumab
A woman with severe hair loss was successfully treated with the drug adalimumab.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Current Treatment of Alopecia Areata
There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.
research Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in the Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design
The combination of cyclosporine and PUVA might help treat severe alopecia areata.
research Alopecia Areata
Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
research Alopecia areata: Clinical presentation, diagnosis, and unusual cases
Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.
research Alefacept for Severe Alopecia Areata
Alefacept does not effectively treat severe alopecia areata.
research Interventions for alopecia areata
Current treatments for alopecia show no significant long-term benefits.
research Familial aggregation of alopecia areata
Alopecia areata, a common autoimmune hair loss condition, often runs in families.
research Guidelines for the management of alopecia areata
The 2003 guidelines suggest that while some treatments can regrow hair in alopecia areata, none alter the disease's progression, and wigs may be the best option for extensive hair loss.
research Systemic Steroids With or Without 2% Topical Minoxidil in the Treatment of Alopecia Areata
Steroids help hair regrowth, and minoxidil slows post-steroid hair loss, but effects are temporary.